Manipulation of biological clocks teaches an important lesson

Synechococcus Elongatus in Petri dish

Evolution is a powerful force that optimises organisms to fit in their environment. But, in our attempts to understand life, biologists often stumble upon natural phenomena that leave them puzzled. According to a new study, solving one such puzzle has helped scientists understand why nature prefers to do things differently than humans would predict.

Proteins, the gears of a cell’s machinery work, are made from combinations of the same 20 building blocks called amino acids. These amino acids get stitched together by enzymes based on instructions from the organism’s DNA. A combination of three letters of the DNA sequence, called codons, instruct enzymes to use one amino acid. But because there are four types of letters (A, T, G and C) in DNA, there are 64 (4^3) ways of making up the three-letter combination of a codon. Because of this an organism has some room for error, because it can now make the same amino acid from three different codons. Consider an organism, for instance, in which the combination CCA codes for the amino acid proline. The same organism will also make proline from three more combinations, namely CCG, CCU and CCC.

It turns out, though not surprisingly, that each organism has a preference for which codon to use for a particular amino acid. Thus if an organism’s DNA carries these preferred codons, then its enzymes can read the code faster and make the protein more quickly. As organisms evolve, biologists assumed, its DNA would be altered to choose preferred codons over others by natural selection.

But that is not what nature does. In reports just published in Nature, two groups of researchers, one led by Carl Johnson at Vanderbilt University and the other by Yi Liu at the University of Texas Southwestern Medical Centre, have found two organisms that do not choose their preferred codons for making specific proteins. If the researchers forced these organism, through genetic manipulation, to use the preferred codons, they found that the mutants did far worse than their wild-types.

Dr Liu chose to work on Neurospora crassa, a fungus. Dr Johnson’s subject was Synechococcus elongatus, a photosynthetic bacteria. In both these organisms, proteins that make up the biological clock were made from codons that the organism did not prefer. “We wondered why evolution hadn’t hit upon that choice,” says Dr Johnson.

Dr Liu and Dr Johnson then rearranged the relevant bits of DNA to create a mutant versions of the two species. Surprisingly, Dr Liu and Dr Johnson got opposing results.

In Neurospora the rearranged letters led to more rapid production of the clock-running proteins, but, instead of making the biological clock more robust, it fell apart. Dr Liu noticed that this was because the faster-produced protein had the correct sequence of amino acids but its folding was not proper.

Proteins, as series of amino acids put together, are long-chain molecules. This gives them the freedom to fold in a number of ways, much like long piece of string can be folded in many ways. These folding patterns are as important for the function of the proteins as is their amino acid sequence. What Dr Liu found was not unusual. If the protein is not given enough time to get its folding tight then it does not function properly, leading to a broken biological clock.

With Synechococcus the result was the opposite. At first Dr Johnson’s experiment seemed to have worked. The mutant bacteria was producing more of the clock-running proteins and its biological cycle had become more robust (sticking closer to 24 hours than its wild variety). But strangely at at temperature of around 20° C the population of the mutant was growing much more slowly than the wild-type. At this temperature the wild-type Synechococcus had a 30-hour biological clock, whereas the mutant was being forced to a 24-hour cycle which Dr Johnson thought would help a photosynthesising bacteria.

Synechococcus’s optimal temperature for growth is about 30° C, which is perhaps what it experiences in its freshwater environment in the summer months. At that temperature the photosynthetic bacteria’s genes are expressed well enough to make its biological clock run closer to the 24-hour cycle where it works for 12 hours when the sun shines and sleeps for 12 hours when there is no sun. But at a lower temperature, which is perhaps what it experiences in the winter months, the gene expression is hampered which results in a 30-hour cycle.

“This 30-hour cycle seemed like an evolutionary adaptation at lower temperature,” says Dr Johnson. Although the reasons are not clear for the adaptation, it may be because of the reduced number of hours of sunlight that are available in winter months. Thus the mutant population with an apparently better biological clock of 24 hours was not doing as well as the wild population with its 30-hour clock. “Better understanding of this bacteria’s cycle is critical to be able to improve its efficiency in biofuels production,” says Dr Johnson.

The bigger lesson, though, is that what humans assumed would be an optimal way of doing things, turns out to be not optimal in evolutionary terms. Codon usage, it seems, is a fundamental part of gene regulation. Both Neurospora and Synechococcus chose to not use the preferred codons because that helped them adapt to their surroundings better. Natural selection works by choosing to make an organism better able to pass on its genes. If it has to do that through an inefficient way of making proteins, then so be it.

UPDATE (18 Feb; 8.53 am): It was incorrectly implied that proline has three codons. In fact, proline has four codons.

References:

  1. Liu et al., Non-optimal codon usage affects expression, structure and function of clock protein FRQ, Nature, 2013.
  2. Johnson et al., Non-optimal codon usage is a mechanismto achieve circadian clock conditionality, Nature, 2013.

Drug development: Teaching old pills new tricks

Exploding research costs and falling sales: there seems to be no cure for the pharma industry’s two big afflictions. But it may have found a way to both cut costs and open up new markets: repurposing drugs already approved for treatment of one disease or those that failed to gain approval in the late stages of development. Alas, this is not as easy as it sounds—mostly for legal reasons.

Finding new uses for old or failed drugs is on average 40% cheaper than inventing a new drug from scratch: it allows to skip the early stages of development. Since coming up with a new drug can cost more than $1 billion, such savings are nothing to sneeze at. Repurposing also trims the risk of failure because new drugs hit a dead end mostly during the early stages of development.

In 2007, a report in Nature, a science journal, counted 41 drugs that have found new uses. But there should be many more, experts say. This is why America’s National Institutes of Health, the country’s biggest government agency financing drug research, and the Medical Research Council, its British counterpart, each have launched new grant programmes. Worth $20m and £10m ($15m) respectively, they are meant to allow university researchers analyse failed drugs from big pharma firms such as Pfizer, AstraZeneca and Eli Lilly and see whether they can be repurposed.

Yet such schemes are not enough, as work by Grant Churchill, a researcher at Oxford University, shows. In a recent paper in Nature Communications, another science journal, he describes how he and his colleagues looked for a drug to treat bipolar disorder, which causes uncontrollable mood swings. Instead of developing a new compound, they tested a library of known ones and found that ebselen, a drug first developed to treat stroke, was a candidate. Their claim, based on animal tests, is that ebselen is as good as and much safer than lithium, currently considered the best treatment for bipolar disorder.

But this was where things hit a hurdle that is hard to overcome. Universities do not have the money to further develop promising drug candidates that need to be tested on a large scale. Expensive human trials are usually carried out by pharma firms, which own the patent for a drug and thus can hope to make their money back. But in the case of many repurposed drugs, like ebselen, the patent has expired. Filing for a new one, which is possible, is not of much help: patients could simply buy versions of the drug which are already available from other makers.

One way of solving this problem would be to change the patent system, for instance by extending the length of patent protection, but this could hamper innovation in other ways. A better solution, argues Benjamin Roin, a law professor at Harvard University, is to have regulators grant the drugmaker that has repurposed the drug some exclusivity and thus time to recover research costs: it is rare that a drug is used in the same form and the same dosage for two different diseases; regulators could wait a few years before they allow other firms to offer the drug for the new purpose. If old drugs can learn new tricks, regulators should do so, too.

First published on economist.com.

References:

  1. Singh et al., A safe lithium mimetic for bipolar disorder, Nature Communications2013.
  2. DiMasi et al., The price of innovation: new estimates of drug development costs, Journal of Health Education2003.
  3. Chong & Sullivan, New uses for old drugs, Nature2007.
  4. Roin, Unpatentable Drugs and the Standards of Patentability, Texas Law Review2009.

Image credit: The Economist

Chest X-rays are not effective at detecting TB infections

Enlarged microscopic image of TB-causing bacteria, Mycobacterium tuberculosis

When I immigrated to the UK as a student, I had to do something that I wasn’t expecting. I had to carry with me a recent chest X-ray. I thought this was completely unnecessary. Why should I be exposed to X-rays for no good reason?

Turned out that there was a reason. It was to stop the spread of tuberculosis (TB) in the UK. Immigrants from sub-Saharan African and the Indian subcontinent are more likely than other immigrants to be infected by TB.  The UK has seen TB cases increase continuously over the past 30 years. Between 1998 and 2009 the numbers rose by 50% to 9040 cases. Most of those affected are foreign-born people. TB infection rates in the UK today are as high as they were in the 1930s, and they are among the highest in any developed country.

The rise in number of cases is despite chest X-ray screening that immigrants have to undergo. That’s because of TB’s quirky ability to show up many years after the TB-causing bacteria infected a person. Researchers find that early detection makes it easier to treat TB, because more severe infections are becoming resistant to current treatments.

With an aim to improve detection rates, Onn Min Kon, a physician at Imperial College London, and colleagues report, in a paper just published in Thorax, that chest X-rays are actually not as effective at detecting TB. Instead, they suggest, the UK government should use an advanced test called interferon-gamma release assays (IGRA).

IGRA works on the principle that when the TB-causing bacteria are exposed to a set of chemicals, which are harmless to humans, it causes them to release a protein called interferon-gamma. If a patient who has been given these chemicals breathes out interferon-gamma, then he is infected by TB (the latent variety or not).

Although a previous consultation with the National Institute for Health and Clinical Excellence had recommended the use of IGRA, it had made that recommendation in combination with chest X-rays. What Dr Kon’s work finds that a more cost-effective, and still efficient, method would be to just use IGRA. It would also spare the patient from being exposed to X-rays!

This research is one among many other papers published in Thorax’s special issue dedicated to TB which coincides with the upcoming World TB day.  

Reference: Pareek, Bond, Shorey, Seneviratne, Guy, White, Lalvani & Min Kon, Community-based evaluation of immigrant tuberculosis screening using interferon γ release assays and tuberculin skin testing: observational study and economic analysis, Thorax 2013http://dx.doi.org/10.1136/thoraxjnl-2011-201542

Image from here.